CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash Flows From Operating Activities:
Net Loss	$ (6,892,545)	$ (7,983,738)	$ (10,292,183)	$ (8,678,347)	$ (14,876,283)	$ (18,970,530)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization					407,680	380,372
Stock-based Compensation					(526,168)	3,018,628
Warrant Modification Expense	837,322		0		837,322	0
Increase in Inventory Reserves					12,000	192,000
Amortization of Right of Use Asset					748,160	975,947
Amortization of Debt Financing Costs and Accretion of Debt Discount					107,527	0
Loss (Gain) on Disposal of Assets					6,048	(300)
Realized (Gain) on Sale of Investments Available-for-Sale					(3,996)	(18,023)
Foreign Currency Translation Adjustment					6,147	144
Changes in Assets and Liabilities:
Decrease in Accounts Receivable, net					637,432	1,590,656
Decrease in Insurance Receivable					0	371,217
(Increase) Decrease in Inventory					(1,302,270)	66,141
(Increase) Decrease in Prepaid and Other Assets					(607,574)	125,750
Increase (Decrease) in Accounts Payable					294,816	(426,772)
Increase (Decrease) in Settlement Payable					(104,000)	13,332
Decrease in Lease Liability					(703,327)	(977,636)
Decrease in Other Liabilities					(95,728)	(992,909)
Decrease in Deferred License Revenue					(992,073)	(1,126,434)
Changes in Assets and Liabilities					(2,872,724)	(1,356,655)
Cash Used In Operating Activities					(16,154,287)	(15,778,417)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale					(16,513,592)	(21,774,410)
Sale of Investments Available-for-Sale					17,497,153	18,798,678
Purchase of Equipment					(283,462)	(305,030)
Purchase of Research and Development Licenses (Related Party)					0	(500,000)
Cash Provided By (Used In) Investing Activities					700,099	(3,780,762)
Cash Flows From Financing Activities:
Proceeds from Term Loan					22,500,000	0
Debt Issuance Costs					(1,342,578)	0
Payments on Short Term Note Payable					(763,421)	0
Proceeds from the Issuance of Common Stock / Public Offering					2,034,073		$ 5,383,079
Offering Costs from the Issuance of Common Stock / Public Offering					(56,443)		(309,479)
Proceeds from the Exercise of Employee Stock Options					0	147,900
Repurchase of Common Stock to Pay Employee Withholding Taxes					(18,863)	(95,429)
Cash Provided By Financing Activities					30,356,725	18,262,358
Increase (Decrease) In Cash and Cash Equivalents					14,902,537	(1,296,821)
Cash and cash equivalents At Beginning Of Period		$ 11,794,526		$ 22,713,980	11,794,526	22,713,980	22,713,980
Cash and cash equivalents At End Of Period	$ 26,697,063		$ 21,417,159		26,697,063	21,417,159	$ 11,794,526
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest					409,931	0
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale					(12,411)	4,265
Insurance Financing Note Payable					0	1,908,554
Fair Value of Warrants issued related to Debt Financing					500,736	0
Public offering
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering					8,147,871	17,500,002
Offering Costs from the Issuance of Common Stock / Public Offering					(143,914)	(1,379,323)
At-the-market offering
Cash Flows From Financing Activities:
Proceeds from the Issuance of Common Stock / Public Offering					2,034,073	2,296,235
Offering Costs from the Issuance of Common Stock / Public Offering					$ (56,443)	$ (207,027)